Details

Autor(en) / Beteiligte

• Gonzalez Gomez, C. A.
• Cosatti, M.
• Castro Coello, V. V.
• Haye, M.
• Tissera, Y.
• Reyes, A. A.
• Albiero, J. A.
• Ornella, S.
• Alba, P.
• Gobbi, C.
• Gamba, M. J.
• Exeni, I. E.
• Cusa, A.
• Gallino Yanzi, J.
• Bellomio, V. I.
• Gomez, G.
• Zelaya, D.
• Takashima, L.
• Carlevaris, L.
• Correa, M. D. L. A.
• Rojas Tessel, R.
• García, M.
• German, N.
• Mercé, A. L.
• Bertoli, A.
• Aguero, S. E.
• Calvo, M. E.
• Martire, V.
• Mauri, M.
• Martin, M. L.
• Picco, E.
• Castrillon Bustamante, D.
• Ibañez Zurlo, L.
• Tamborenea, M. N.
• Subils, G. C.
• Vasquez, D. L.
• Soares de Souza, S.
• Herscovich, N.
• Raiti, L.
• Cosentino, V.
• Rodriguez, F.
• Ledesma, C.
• Diaz, M. P.
• Mamani Ortega, M. L.
• Castaño, M. S.
• Gómez, G.
• Roberts, K.
• Quintana, R.
• Isnardi, C. A.
• Pons-Estel, G.
• Pisoni, C.

Titel

AB1101 PREVALENCE OF LONG COVID IN RHEUMATIC DISEASE PATIENTS: ANALYSIS OF SAR COVID REGISTRY

Ist Teil von

• Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.1668-1669

Erscheinungsjahr

2022

Beschreibungen/Notizen

• Background Persistent symptoms after acute COVID have been described previously. Main symptoms reported are fatigue, arthralgias, myalgias and mental sickness. Definition and methods vary widely. 1 Objectives To asses prevalence and related factors to long COVID in a retrospective cohort of patients with rheumatic diseases from Argentina. Methods A total of 1915 patients were registered from August 18th, 2020 to July 29th, 2021. Patients > 18 years old, with rheumatic disease and confirmed infection by SARS-CoV-2 (antigen or RT-PCR) were included. Those dead, with unknown outcome, wrong date or missing data were excluded. Demographic data, comorbidities, rheumatic disease, and characteristics of SARS-CoV-2 infection were recorded. Long COVID was defined according to NICE guidelines (persistent symptoms for more than 4 weeks, without alternative diagnosis). Long COVID symptoms were defined by rheumatologist. Severity of infection was classified according to WHO ordinal scale. We used descriptive statistics, univariate model (Student’s test, chi square test, ANOVA) and multivariate logistic regression analysis. Results 230 (12%) had long COVID. Median age was 51 (IQR 40-61]) years, 82% were females, 51% were not caucasian. Median of education was 13.3 years (IQR 12 – 16), 79 % had private health insurance and 55 % were employed. Nearly half (n=762, 46%) had comorbidities, the most prevalent was hypertension (n=396, 24%). The most frequent rheumatic diseases were rheumatoid arthritis (n=719, 42%) and systemic lupus erythematosus (n=280, 16 %). Most were in low activity/remission (79%), used Conventional DMARD (n=773 patients, 45%) and steroids (n=588, 34%) at low dose (n=415, 71%). Main laboratory findings were abnormal D-dimer (n=94, 28%) and leukopenia (n=93, 26%). Most patients had a WHO ordinal scale < 5 (n=1472, 86%). Median of hospitalization at intensive care unit (ICU) was 8 days [IQR 5, 13]. Treatment for SARS-CoV-2 infection (steroids, anticoagulation, azithromycin, convalescent plasma) was used in 461 (27%) patients. Most of long COVID (n= 152, 69%) reported 1 symptom, the most frequent was fatigue (n= 55, 22%). Figure 1. Univariate analysis is presented in Table 1. In multivariate logistic regression analysis non-caucasian ethnicity OR 1.44 (1.07-1.95), years of education OR 1.05 (1-1.09), treatment with cyclophosphamide OR 11.35 (1.56-112.97), symptoms of COVID – 19 OR 13.26 (2.75-242.08), severity scale WHO ≥ 5 OR 2.46 (1.68-3.57), and ICU hospitalization days OR 1.09 (1.05-1.14) were factors associated to long COVID. Table 1. Univariate analysis of long COVID syndrome in SAR – COVID registry Variable Acute COVID n=1486 Long COVID n=221 P value Age, years, median [IQR] 51 [40, 60] 54 [42, 62] 0.032 Caucasian, n (%) 744 (48) 132 (53) 0.227 Female sex, n (%) 1242 (80) 215 (86) 0.066 Education, years, median [IQR] 12 [10, 17] 13 [12, 16] - Private health insurance, n (%) 1161 (79) 181 (82) 0.325 Smoking, n (%) 381 (25) 71 (29) 0.224 Comorbidities, n (%) 650 (45) 108 (52) 0.066 Dyslipidemia, n (% ) 173 (12 ) 39 (19 ) 0.008 Hypertension, n (% ) 332 (23 ) 60 (29 ) 0.053 Low activity/remission disease, n (%) 1140 (80) 179 (77) 1 Rheumatoid arthritis, n (%) 623 (42) 96 (42) 1 Systemic lupus erythematosus, n (%) 243 (16) 37 (16) 0.996 DMARD, n (%) 664 (45) 109 (47) 0.486 Cyclophosphamide, n (% ) 3 (0.2 ) 3 (1 ) 0.035 Rituximab, n (% ) 19 (1 ) 9 (34 ) 0.008 Lymphocyte 66 (23 ) 19 (30 ) 0.011 <1.500 / mm3, n (% ) Ferritin > 2000 ng/ml, n (% ) 32 (11 ) 16 (25 ) 0.011 ICU hospitalization, days, 7 [4, 10] 10 [8, 24] <0.001 median [IQR] Treatment for COVID-19, n (% ) 394 (27 ) 91 (41 ) <0.001 Conclusion Prevalence of long COVID was 12%. Non-caucasian ethnicity, higher education, treatment with cyclophosphamide, symptoms of COVID – 19, severe disease and ICU hospitalization days were related to long COVID. References [1]Cabrera Martimbianco AL, Pacheco RL, Bagattini ÂM, Riera R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int J Clin Pract. Disclosure of Interests None declared